Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion

In: O'Brn SG, Guhot F, Larson RA, Gathmann BaccaranM, Cervantes F, Cornelsen JJ, Fcher T, Hochhaus A, Hughes T, Lechner K, Nlsen JL, Rousselot P, Refers J, Sagl G, Shepherd J, Sonsson B, Gratwohl A, Goldman JM, Kantarjn H, Taylor K, Verhoef G, Bolton AE, Capdevle R, Druker BJ; vestators. at compared wh terferon and low-dose cytarabe for newly dgnosed chron-phase chron myelo leukem. N Engl J Med. 2003 Mar 13;348(11):994-1004. do 10.1056/NEJMoa022457. Hughes TP, Kaeda J, Branford S, RudzkZ, Hochhaus A, Hensley ML, Gathmann Bolton AE, van Hoomsen , Goldman JM, Radh JP; ternatnal Randomed Study of terferon versus ST71 () Study Group. Frequency of major molecular responses to at or terferon alfa plus cytarabe newly dgnosed chron myelo leukem. N Engl J Med. 2003 Oct 9;349(15):1423-32. do 10.1056/NEJMoa030513. Druker BJ, Guhot F, O'Brn SG, Gathmann Kantarjn H, Gattermann N, Deger MW, Sver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrove JL, Rousselot P, Refers J, Cornelsen JJ, Hughes T, Ag H, Fcher T, Verhoef G, Shepherd J, Sagl G, Gratwohl A, Nlsen JL, Radh JP, Sonsson B, Taylor K, BaccaranM, So C, Letvak L, Larson RA; vestators. Fe-year follow-up of patnts receg at for chron myelo leukem. N Engl J Med. 2006 Dec 7;355(23):2408-17. do 10.1056/NEJMoa062867. Jabbour E, Cortes JE, Kantarjn HM. Molecular monorg chron myelo leukem: response to tyrose kase hors and prognost platns. Cancer. 2008 May 15;112(10):2112-8. do 10.1002/cncr.23427. de Lavallade H, Apperley JF, Khorashad JS, Mojkov D, Re AG, Bua M, Szydlo R, Olavarr E, Kaeda J, Goldman JM, Mar D. at for newly dgnosed patnts wh chron myelo leukem: cence of sustaed responses an tentn-to-treat analys. J Cl Oncol. 2008 Jul 10;26(20):3358-63. do 10.1200/JCO.2007.15.8154. Epub 2008 Jun 2. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Deverg A, FrassonF, Gahrton G, Kolb HJ, Nderwser D, Ruutu T, Vernant JP, de Wte T, Apperley J. Rk assessment for patnts wh chron myelo leukaem before allogene blood or marrow transplantatn. Chron Leukem Workg Party of the European Group for Blood and Marrow Transplantatn. Lancet. 1998 Oct 3;352(9134):1087-92. do 10.1016/s0140-6736(98)03030-x. Passweg JR, Walker SobocskKA, Kle JP, Horowz MM, Galt SA; Chron Leukem Study Wrg Commtee of the ternatnal Bone Marrow Transplant Regtry. Valatn and extensn of the EBMT Rk Score for patnts wh chron myelo leukaem (CML) receg allogene haematopot stem cell transplants. Br J Haematol. 2004 Jun;125(5):613-20. do 10.1111/j.1365-2141.2004.04955.x. BaccaranM, Sagl G, Goldman J, Hochhaus A, Sonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deger M, Gratwohl A, Guhot F, Horowz M, Hughes T, Kantarjn H, Larson R, Nderwser D, Sver R, Hehlmann R; European LeukemNet. Evolvg concepts the management of chron myelo leukem: recommendatns from an expert panel on behalf of the European LeukemNet. Blood. 2006 Sep 15;108(6):1809-20. do 10.1182/blood-2006-02-005686. Epub 2006 May 18. Goldman JM. How treat chron myelo leukem the at era. Blood. 2007 Oct 15;110(8):2828-37. do 10.1182/blood-2007-04-038943. Epub 2007 Jul 12. Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion and Preemptive Donor Lymphocyte Infusion.

Online report